Pharmacogenomic strategy for individualizing antidepressant therapy

Keh Ming Lin, Roy H. Perlis, Yu-Jui Yvonne Wan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of "individualized" ("personalized") medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalDialogues in Clinical Neuroscience
Volume10
Issue number4
StatePublished - 2008
Externally publishedYes

Fingerprint

Precision Medicine
Pharmacogenetics
Antidepressive Agents
Diffusion of Innovation
Therapeutic Uses
Product Packaging
Ethics
Pharmacokinetics
Technology
Drug Therapy
Therapeutics

Keywords

  • Antidepressant
  • Individualized medicine
  • Personalized medicine
  • Pharmacogenetic
  • Pharmacogenomic
  • Psychopharmacology
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Pharmacogenomic strategy for individualizing antidepressant therapy. / Lin, Keh Ming; Perlis, Roy H.; Wan, Yu-Jui Yvonne.

In: Dialogues in Clinical Neuroscience, Vol. 10, No. 4, 2008, p. 401-408.

Research output: Contribution to journalArticle

@article{0ae52cbb544244ffbecfb0bcf400db96,
title = "Pharmacogenomic strategy for individualizing antidepressant therapy",
abstract = "Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of {"}individualized{"} ({"}personalized{"}) medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.",
keywords = "Antidepressant, Individualized medicine, Personalized medicine, Pharmacogenetic, Pharmacogenomic, Psychopharmacology, Treatment response",
author = "Lin, {Keh Ming} and Perlis, {Roy H.} and Wan, {Yu-Jui Yvonne}",
year = "2008",
language = "English (US)",
volume = "10",
pages = "401--408",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "4",

}

TY - JOUR

T1 - Pharmacogenomic strategy for individualizing antidepressant therapy

AU - Lin, Keh Ming

AU - Perlis, Roy H.

AU - Wan, Yu-Jui Yvonne

PY - 2008

Y1 - 2008

N2 - Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of "individualized" ("personalized") medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.

AB - Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of "individualized" ("personalized") medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.

KW - Antidepressant

KW - Individualized medicine

KW - Personalized medicine

KW - Pharmacogenetic

KW - Pharmacogenomic

KW - Psychopharmacology

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=59149085326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149085326&partnerID=8YFLogxK

M3 - Article

C2 - 19170397

AN - SCOPUS:59149085326

VL - 10

SP - 401

EP - 408

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 4

ER -